← Leaderboards
Craig R Rush
University Of Kentucky
$27,535,139
Attributed
$27,999,054
Total exposure
28
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,999,054 · 28
By mechanism
R01$19,105,428 · 13
T32$5,159,015 · 2
M01$1,178,476 · 9
TL1$974,559 · 1
R34$674,992 · 1
R56$532,269 · 1
Top collaborators
- William Walton Stoops3 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Sharon L. Walsh$101,480,172
- Joshua Anthony Lile$8,940,358
- John M Littleton$19,398,400
- Jessica J Weafer$5,354,790
- William Walton Stoops$15,269,484
Others in their field
Top investigators on “Cocaine”
- Sten H Vermund · University Of Alabama At Birmingham$115,253,143
- Fred M Gordin · Social And Scientific Systems, Inc.$44,160,542
- Eric J Nestler · Icahn School Of Medicine At Mount Sinai$42,690,128
- Joel Gelernter · Washington University$34,364,949
- Michael A Nader · Emory University$33,226,167
- Shenghan Lai · University Of Miami Coral Gables$31,568,530
Research focus
CocaineMaintenanceQuestionnairesBehavioralProceduresPharmaceutical PreparationsClinical ResearchAttenuatedDosePharmacotherapyBehaviorDrug AbuseSelf AdministrationClinical TrialsSafetyPublic Health Medicine (Field)Research StudyAdmission ActivityAmericanLaboratoriesReportingLaboratory StudyDopaminePrograms
Grant awards (86)
Research Training in Drug Abuse Behavior$372,109
T32 · FY2025 · DA
Research Training in Drug Abuse Behavior$201,327
T32 · FY2024 · DA
NRSA Training Core$470,012
TL1 · FY2023 · TR · contact PI
Research Training in Drug Abuse Behavior$354,395
T32 · FY2023 · DA · contact PI
Research Training in Drug Abuse Behavior$399,016
T32 · FY2022 · DA · contact PI
NRSA Training Core$41,492
TL1 · FY2022 · TR · contact PI
NRSA Training Core$463,055
TL1 · FY2021 · TR · contact PI
Research Training in Drug Abuse Behavior$179,517
T32 · FY2021 · DA · contact PI
A Novel Drug Combination for Alcohol-Use Disorders: A Human Laboratory Study$622,574
R01 · FY2020 · AA · contact PI
Research Training in Drug Abuse Behavior$372,780
T32 · FY2020 · DA · contact PI
A Novel Drug Combination as a Pharmacotherapeutic for Methamphetamine-Use Disorder$615,723
R01 · FY2019 · DA · contact PI
A Novel Drug Combination for Alcohol-Use Disorders: A Human Laboratory Study$609,416
R01 · FY2019 · AA · contact PI
Research Training in Drug Abuse Behavior$360,364
T32 · FY2019 · DA · contact PI
A Novel Drug Combination for Alcohol-Use Disorders: A Human Laboratory Study$609,013
R01 · FY2018 · AA · contact PI
Research Training in Drug Abuse Behavior$324,631
T32 · FY2018 · DA · contact PI
Topiramate-Phentermine Combinations for Cocaine Dependence$632,059
R01 · FY2017 · DA · contact PI
Research Training in Drug Abuse Behavior$342,317
T32 · FY2017 · DA · contact PI
A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use$225,750
R34 · FY2017 · DA · contact PI
Monoamine Uptake Inhibition for Cocaine Dependence: A Novel Drug Combination$532,269
R56 · FY2016 · DA · contact PI
Research Training in Drug Abuse Behavior$331,522
T32 · FY2016 · DA · contact PI
A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use$223,492
R34 · FY2016 · DA · contact PI
Topiramate-Phentermine Combinations for Cocaine Dependence$622,578
R01 · FY2015 · DA · contact PI
A Novel Anti Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence$609,399
R01 · FY2015 · DA · contact PI
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse$598,459
R01 · FY2015 · DA · contact PI
Research Training in Drug Abuse Behavior$289,446
T32 · FY2015 · DA · contact PI
A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use$225,750
R34 · FY2015 · DA · contact PI
Topiramate-Phentermine Combinations for Cocaine Dependence$638,985
R01 · FY2014 · DA · contact PI
A Novel Anti Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence$618,681
R01 · FY2014 · DA · contact PI
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse$605,250
R01 · FY2014 · DA · contact PI
Research Training in Drug Abuse Behavior$315,866
T32 · FY2014 · DA · contact PI
Buspirone as a Candidate Medication for Methamphetamine Abuse$167,185
R21 · FY2014 · DA · contact PI
Research Training in Drug Abuse Behavior$97,108
T32 · FY2014 · DA · contact PI
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse$604,690
R01 · FY2013 · DA · contact PI
Agonist Replacement Therapy for Methamphetamine Dependence: Human Lab Studies$337,642
R01 · FY2013 · DA · contact PI
Research Training in Drug Abuse Behavior$320,745
T32 · FY2013 · DA · contact PI
Buspirone as a Candidate Medication for Methamphetamine Abuse$207,130
R21 · FY2013 · DA · contact PI
A Novel Anti Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence$629,694
R01 · FY2012 · DA · contact PI
GABAA Modulation as a Target for Developing Medications for Methamphetamine Abuse$351,710
R01 · FY2012 · DA · contact PI
Agonist Replacement Therapy for Methamphetamine Dependence: Human Lab Studies$351,710
R01 · FY2012 · DA · contact PI
Research Training in Drug Abuse Behavior$313,371
T32 · FY2012 · DA · contact PI
GABAA Modulation as a Target for Developing Medications for Methamphetamine Abuse$351,710
R01 · FY2011 · DA · contact PI
Agonist Replacement Therapy for Methamphetamine Dependence: Human Lab Studies$351,710
R01 · FY2011 · DA · contact PI
Research Training in Drug Abuse Behavior$290,449
T32 · FY2011 · DA · contact PI
Agonist Replacement Therapy for Methamphetamine Dependence: Human Lab Studies$362,588
R01 · FY2010 · DA · contact PI
Research Training in Drug Abuse Behavior$294,052
T32 · FY2010 · DA · contact PI
Agonist Replacement Therapy for Methamphetamine Dependence: Human Lab Studies$366,250
R01 · FY2009 · DA · contact PI
GABAA Modulation as a Target for Developing Medications for Methamphetamine Abuse$366,250
R01 · FY2009 · DA · contact PI
Agonist Replacement Therapy for Cocaine Dependence: Identifying Novel Medications$348,516
R01 · FY2009 · DA · contact PI
Stimulant Abuse Pharmacotherapy: Novel Antipsychotics$306,293
R01 · FY2009 · DA · contact PI
Agonist Replacement Therapy for Cocaine Dependence: Identifying Novel Medications$348,516
R01 · FY2008 · DA · contact PI
Preventing Cocaine Relapse: Developing Pharmacotherapies$340,325
R01 · FY2008 · DA · contact PI
GABAA Modulation as a Target for Developing Medications for Methamphetamine Abuse$329,625
R01 · FY2008 · DA · contact PI
Stimulant Abuse Pharmacotherapy: Novel Antipsychotics$306,293
R01 · FY2008 · DA · contact PI
Agonist Replacement Therapy for Cocaine Dependence: Identifying Novel Medications$355,629
R01 · FY2007 · DA · contact PI
Preventing Cocaine Relapse: Developing Pharmacotherapies$347,271
R01 · FY2007 · DA · contact PI
Stimulant Abuse Pharmacotherapy: Novel Antipsychotics$312,545
R01 · FY2007 · DA · contact PI
BEHAVIORAL EFFECTS OF DRUGS (INPATIENT): 08$311,575
M01 · FY2007 · RR · contact PI
BEHAVORIAL EFFECTS OF DRUGS (INPATIENT): 06$138,284
M01 · FY2007 · RR · contact PI
BEHAVIORAL EFFECTS ON DRUGS: INPATIENT (09)$18,714
M01 · FY2007 · RR · contact PI
UNIVERSITY OF KENTUCKY LABORATORY OF HUMAN BEHAVIORAL PHARMACOLOGY SCREENING$17,342
M01 · FY2007 · RR · contact PI
Agonist Replacement Therapy for Cocaine Dependence: Identifying Novel Medications$366,209
R01 · FY2006 · DA · contact PI
Preventing Cocaine Relapse: Developing Pharmacotherapies$357,643
R01 · FY2006 · DA · contact PI
Stimulant Abuse Pharmacotherapy: Novel Antipsychotics$321,807
R01 · FY2006 · DA · contact PI
BEHAVORIAL EFFECTS OF DRUGS 06 B$258,290
M01 · FY2006 · RR · contact PI
Human Cocaine Discrimination$215,758
R01 · FY2006 · DA · contact PI
BEHAVIORAL EFFECTS OF DRUGS 08$39,288
M01 · FY2006 · RR · contact PI
Preventing Cocaine Relapse: Developing Pharmacotherapies$366,250
R01 · FY2005 · DA
Stimulant Abuse Pharmacotherapy: Novel Antipsychotics$329,175
R01 · FY2005 · DA
Human Cocaine Discrimination$220,950
R01 · FY2005 · DA
BEHAVIORAL EFFECTS OF DRUGS: INPATIENT (05)$31,437
M01 · FY2005 · RR
Behavioral Effects of Drugs-Inpatient (02)$314,237
M01 · FY2004 · RR
ASSESSING ABUSE POTENTIAL IN HUMAN--CNS STIMULANTS$289,600
R01 · FY2004 · DA
Human Cocaine Discrimination$220,500
R01 · FY2004 · DA
Behavioral Effects of Drugs: Inpatient (05)$49,309
M01 · FY2004 · RR
GABA Agonists as Pharmacotherapies for Cocaine Abuse$325,800
R01 · FY2003 · DA
ASSESSING ABUSE POTENTIAL IN HUMAN--CNS STIMULANTS$289,600
R01 · FY2003 · DA
Human Cocaine Discrimination$219,000
R01 · FY2003 · DA
GABA Agonists as Pharmacotherapies for Cocaine Abuse$325,800
R01 · FY2002 · DA
ASSESSING ABUSE POTENTIAL IN HUMAN--CNS STIMULANTS$289,600
R01 · FY2002 · DA
BEHAVIORAL EFFECTS OF DRUGS--INPATIENT$0
M01 · FY2002 · RR
GABA Agonists as Pharmacotherapies for Cocaine Abuse$325,800
R01 · FY2001 · DA
ASSESSING ABUSE POTENTIAL IN HUMAN--CNS STIMULANTS$289,767
R01 · FY2001 · DA
COCAINE DISCRIMINATION AND PHARMACOLOGICAL SPECIFICITY$254,236
R01 · FY2001 · DA
BEHAVIORAL EFFECTS OF DRUGS--INPATIENT$0
M01 · FY2001 · RR
COCAINE DISCRIMINATION AND PHARMACOLOGICAL SPECIFICITY$246,829
R01 · FY2000 · DA
BEHAVIORAL EFFECTS OF DRUGS--INPATIENT$0
M01 · FY2000 · RR